Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1999 2
2000 2
2008 1
2009 2
2010 1
2011 1
2016 2
2018 1
2019 1
2020 1
2021 2
2022 3
2023 3
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
The Steno 1 study: Multifactorial intervention to reduce cardiovascular disease in type 1 diabetes-rationale and protocol of the prospective, randomized, open-labelled multicentre study.
Stougaard EB, Andersen MR, Bagger JI, Søndergaard E, Østergaard JA, Curovic VR, Persson F, Almdal T, Mathiesen AS, Andries A, Bohl M, Nørgaard LJ, Dejgaard TF, Dørfinger GH, Gustenhoff P, Gæde PH, Hamid YH, Johannesen HL, Juhl CB, Jørgensen ME, Kielgast U, Kofoed-Enevoldsen A, Lindhardt M, Mortensen LS, Thomsen HH, Stidsen J, Sørensen LP, Urhammer S, Rossing P; Steno 1 Study Group. Stougaard EB, et al. Diabetes Obes Metab. 2025 Oct;27(10):5432-5443. doi: 10.1111/dom.16606. Epub 2025 Jul 29. Diabetes Obes Metab. 2025. PMID: 40726451
Effect of insulin degludec versus insulin glargine U100 on nocturnal glycaemia assessed by plasma glucose profiles in people with type 1 diabetes prone to nocturnal severe hypoglycaemia.
Brøsen JMB, Agesen RM, Kristensen PL, Alibegovic AC, Andersen HU, Beck-Nielsen H, Gustenhoff P, Hansen TK, Hedetoft C, Jensen T, Stolberg CR, Juhl CB, Lerche SS, Nørgaard K, Parving HH, Tarnow L, Thorsteinsson B, Pedersen-Bjergaard U. Brøsen JMB, et al. Among authors: hedetoft c. Diabetes Obes Metab. 2023 Jun;25(6):1557-1565. doi: 10.1111/dom.15003. Epub 2023 Feb 28. Diabetes Obes Metab. 2023. PMID: 36749303 Clinical Trial.
Effects of 18-months metformin versus placebo in combination with three insulin regimens on RNA and DNA oxidation in individuals with type 2 diabetes: A post-hoc analysis of a randomized clinical trial.
Larsen EL, Kjær LK, Lundby-Christensen L, Boesgaard TW, Breum L, Gluud C, Hedetoft C, Krarup T, Lund SS, Mathiesen ER, Perrild H, Sneppen SB, Tarnow L, Thorsteinsson B, Vestergaard H, Poulsen HE, Madsbad S, Almdal TP. Larsen EL, et al. Among authors: hedetoft c. Free Radic Biol Med. 2022 Jan;178:18-25. doi: 10.1016/j.freeradbiomed.2021.11.028. Epub 2021 Nov 22. Free Radic Biol Med. 2022. PMID: 34823018 Free article. Clinical Trial.
Continuous Glucose Monitoring-Recorded Hypoglycemia with Insulin Degludec or Insulin Glargine U100 in People with Type 1 Diabetes Prone to Nocturnal Severe Hypoglycemia.
Brøsen JMB, Agesen RM, Alibegovic AC, Ullits Andersen H, Beck-Nielsen H, Gustenhoff P, Krarup Hansen T, Hedetoft CGR, Jensen TJ, Stolberg CR, Bogh Juhl C, Lerche SS, Nørgaard K, Parving HH, Tarnow L, Thorsteinsson B, Pedersen-Bjergaard U. Brøsen JMB, et al. Among authors: hedetoft cgr. Diabetes Technol Ther. 2022 Sep;24(9):643-654. doi: 10.1089/dia.2021.0567. Epub 2022 Jun 22. Diabetes Technol Ther. 2022. PMID: 35467938 Free article. Clinical Trial.
Comparison of treatment with insulin degludec and glargine U100 in patients with type 1 diabetes prone to nocturnal severe hypoglycaemia: The HypoDeg randomized, controlled, open-label, crossover trial.
Pedersen-Bjergaard U, Agesen RM, Brøsen JMB, Alibegovic AC, Andersen HU, Beck-Nielsen H, Gustenhoff P, Hansen TK, Hedetoft C, Jensen TJ, Juhl CB, Jensen AK, Lerche SS, Nørgaard K, Parving HH, Sørensen AL, Tarnow L, Thorsteinsson B. Pedersen-Bjergaard U, et al. Among authors: hedetoft c. Diabetes Obes Metab. 2022 Feb;24(2):257-267. doi: 10.1111/dom.14574. Epub 2021 Nov 2. Diabetes Obes Metab. 2022. PMID: 34643020 Free PMC article. Clinical Trial.
Leptin: a potent inhibitor of insulin secretion.
Fehmann HC, Peiser C, Bode HP, Stamm M, Staats P, Hedetoft C, Lang RE, Göke B. Fehmann HC, et al. Among authors: hedetoft c. Peptides. 1997;18(8):1267-73. doi: 10.1016/s0196-9781(97)00135-6. Peptides. 1997. PMID: 9396072
Quality of life, patient satisfaction, and cardiovascular outcomes of the randomised 2 x 3 factorial Copenhagen insulin and Metformin therapy (CIMT) trial - A detailed statistical analysis plan.
Olsen MH, Almdal TP, Madsbad S, Ovesen C, Gluud C, Sneppen SB, Breum L, Hedetoft C, Krarup T, Lundby-Christensen L, Mathiesen ER, Røder ME, Vestergaard H, Wiinberg N, Jakobsen JC. Olsen MH, et al. Among authors: hedetoft c. Contemp Clin Trials Commun. 2023 Feb 24;33:101095. doi: 10.1016/j.conctc.2023.101095. eCollection 2023 Jun. Contemp Clin Trials Commun. 2023. PMID: 36923108 Free PMC article.
Metformin may adversely affect orthostatic blood pressure recovery in patients with type 2 diabetes: substudy from the placebo-controlled Copenhagen Insulin and Metformin Therapy (CIMT) trial.
Hansen CS, Lundby-Christiansen L, Tarnow L, Gluud C, Hedetoft C, Thorsteinsson B, Hemmingsen B, Wiinberg N, Sneppen SB, Lund SS, Krarup T, Madsbad S, Almdal T, Carstensen B, Jørgensen ME; CIMT study group. Hansen CS, et al. Among authors: hedetoft c. Cardiovasc Diabetol. 2020 Sep 26;19(1):150. doi: 10.1186/s12933-020-01131-3. Cardiovasc Diabetol. 2020. PMID: 32979921 Free PMC article. Clinical Trial.
[Fatal poisoning with Letigen].
Hedetoft C, Jensen CH, Christensen MR, Christensen O. Hedetoft C, et al. Ugeskr Laeger. 1999 Dec 13;161(50):6937-8. Ugeskr Laeger. 1999. PMID: 10643382 Danish.
21 results